

Figure 1
Schematic Of Complexation Process




Figure 2

LHRH Synthetic Immunogens:CpG1 Oligonucleotide Complexes
Particle Size Distribution Vs. Relative Molar Charge Ratio




Figure 3
Schematic Of W/O Emulsion Process Via Homogenization Or Extrusion




Figure 4
Homogenized W/O Emulsion
LHRH Peptides : CpG1 Oligonucleotides (ratio 4:1)




Figure 5

Extruded W/O Emulsion
LHRH Peptides : CpG1 Oligonucleotides (ratio 4:1)




Figure 6
Schematic Of Polymer In-Situ Gel Process Via Reconstitution




Figure 7

(IgE Peptides/CpG1 Complexes + Homogenized W/O Emulsions)
3 immunizations (week 0, 3, 6), Bleeds (week 3, 5, 9, 11, 17)




Figure 8
(CD4 Peptides/CpG2 Complexes + Homogenized W/O Emulsions)
3 immunizations (week 0, 3, 6), Bleeds (week 3, 5, 9, 11, 17)




Figure 9
 (IgE Peptides/CpG1 Complexes + Extruded W/O Emulsions)
 3 immunizations (week 0, 3, 6), Bleeds (week 3, 5, 9, 11, 17)




Figure 10
 (CD4 Peptides/CpG2 Complexes + Extruded W/O Emulsions)
 3 immunizations (week 0, 3, 6), Bleeds (week 3, 5, 9, 11, 17)




Figure 11
 (IgE Peptides/CpG1 Complexes + PLGA/DMSO Gels)
 Single Dose Immunization, Bleeds (week 3, 6, 9, 12)




Figure 12
(CD4 Peptides/CpG2 Complexes + PLGA/DMSO Gels)
Single Dose Immunization, Bleds (week 3, 6, 9,12)

